Healthpeak's Options Hedge Persists Even as Shorts Keep Covering

The defining feature of DOC positioning ahead of tomorrow's Q3 print is a persistent gap: options traders have grown more defensive over the past two sessions while short sellers continue to pare exposure.

The put/call ratio closed at 0.52 on November 3, nearly 1.9 standard deviations above its 20-day average of 0.43. That is the most protective options posture the stock has carried into a print in recent months, though still well below the 52-week extreme of 1.59. The shift arrived as the stock gained 2.8% over the past week to $19.56, outpacing a median decline of roughly 0.5% among its closest peers. HR rose 6.3% over the same period and ARE fell 1.9%, so DOC's weekly gain was not a broad sector lift; it reflected something more specific to this name.

The short book tells the opposite story from options. Short interest rose a modest 2.5% in the most recent session but remains down nearly 2% on the week and down more than 3.5% on the month, leaving bears holding 3.15% of the free float. That is well off the mid-October peak of roughly 28 million shares. Borrow availability is extraordinary: at 2,597% of current short interest, there is no constraint on either adding or covering positions. Cost to borrow has crept up 29% over the week to 0.46%, but that remains negligible in absolute terms. The short score has also drifted lower, from 38.8 on October 20 to 37.0 as of November 2. The lending market is under no stress.

Analysts cut targets consistently in the weeks before this report, with Wells Fargo dropping to $19 from $22 on October 19, Barclays trimming to $21 from $24 on October 13, and UBS lowering to $20 from $21.50 on the same day. All three maintained neutral-equivalent ratings. The mean target now sits at $22.39, implying roughly 14% upside from the current price. The bear case centers on Lab tenant credit risk, slow capital formation weighing on life-science leasing, and a FFOPS growth rate that multiple analysts now put at 1% or below through 2027. The bull case rests on roughly 700 properties, the majority in medical office and life science, plus a development pipeline that is around 80% pre-leased and targeting mid-7% stabilized yields. Retail attention, as measured by Wikipedia page views, is running at a z-score of 2.4 above the past 90 days' own history, the highest attention signal in this dataset for the stock, though this measures visibility, not a revenue indicator.

The November 5 print will test whether Lab occupancy has stabilized enough to push guidance toward the higher end of analyst estimates, and whether the development pipeline's pre-leasing rate has held in a capital-constrained environment for life-science tenants.